Tuohy E, Litt E, Alikhan R. Journal of Blood Medicine 2011;2:49–57.
The reference column of Table 1 was incorrect in the published version. The correct Table 1, also amended for clarity, is below.
Table 1.
Pharmacokinetic properties of von Willebrand Factor-containing concentrates
| Product | In vivo vWF:RCo recovery (IU/dL per IU/kg) | In vivo FVIII recovery (IU/dL per IU/kg) | vWF:RCo/FVIII ratio | Source of plasma | Viral inactivation | Vial sizes (IU) | Reference |
|---|---|---|---|---|---|---|---|
| Alphanate | 2.9 ± 1.3 (mean ± SD) | 2.1 ± 0.4 (mean ± SD) | 1.6:1 | USA | SLD Dry heat (80°C for 72 hrs) |
250 500 1000 1500 |
(32) |
| Biostate | 0.85 (0.77–0.92) mean (90% CI) | 1.1 (0.88–1.32) mean (90% CI) | 2.1:1 | Australia | SLD Dry heat (80°C for 72 hrs) |
250 500 |
(29) |
| Factor 8Y | Type 3: 1.4 ± 0.05 Type 2A: 2.0 ± 0.06 Type 1: 2.3 ± 0.5 (mean ± SD) |
Type 3: 2.4 ± 1.1 Type 1: 5.0 ± 4.5 (mean ± SD) |
2:1 | USA | Dry heat (80°C for 72 hrs) |
250 500 |
(31) |
| Fanhdi | 1.9 ± 0.6 | 2.6 ± 0.6 | 1.6:1 | USA | SLD Dry heat (80°C for 72 hrs) |
250 500 1000 1500 |
(33,34) |
| Haemate P/Humate P | 2.1 (1.1–2.7) median (range) | 2.7 (1.9–3.7) median (range) | 2.5:1 | USA, Austria, Germany | Pasteurized (60°C for 10 hrs) |
500 1000 |
(28) |
| Wilfactin | 2.1 ± 0.3 | 5.8 ± 1 IU/dL (FVIII synthesis rate) | 10:1 | Germany, France, Switzerland | SLD Dry heat (80°C for 72 hrs) Nanofiltration (35 nM) |
1000 | (30) |
Abbreviations: SLD, solvent detergent, in viral inactivation column; SD, standard deviation in columns 2 and 3; vWF, von Willebrand factor; vWD, von Willebrand disease; vWF:RCo, vWF ristocetin cofactor.